

**HEALTH TECHNOLOGY APPRAISAL: NICE Health Technology
Appraisal - Appraisal Consultation Document (ACD)**

**On
Sequential use of Adalimumab, etanercept and infliximab for the
treatment of rheumatoid arthritis after failure of a TNH-a inhibitor**

TO: NICE

**FROM: NHS Quality
Improvement Scotland**

1. *Whether you consider that all the relevant evidence has been taken into account.*

Yes There are several other European registries – I do not believe that interrogating these will provide any additional information.

2. *Whether you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence..*

Clinical effectiveness – the information has been very effectively summarised and I agree with the interpretations.

Cost effectiveness – This is not an area of my expertise but the arguments put forward have in view been undertaken with appropriate diligence.

3. *Whether you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS.*

Yes – I agree with all the provisional recommendations and constitute a very useful guidance for clinicians.

26 May 2008

